The Efficacy and Safety of Interferons for the Treatment of Patients with COVID-19: Protocol for Systematic Review and Meta-Analysis of Controlled Trials
Abstract
Context: COVID-19 has been declared a global pandemic by the World Health Organization (WHO), infecting millions worldwide. The use of interferon (INF) subtypes previously examined in the treatment of SARS and MERS is also being initiated in some clinical trials. Although different clinical trials were evaluated IFNs in the treatment of COVID-19, their efficacy and safety remain unknown.
Objectives: This study aimed to systematically assess IFNs efficacy and safety in treating patients with COVID 19.
Methods: The protocol has been registered in the PROSPERO International Prospective Register (CRD42020200643) on 24 July 2020. This protocol has been arranged according to the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) 2015 checklist.
Conclusions: Owing to lack of approved medication for COVID-19 treatment as well as various mutations of this virus, evaluation of the efficacy and safety of medications by various studies may help in finding treatments with high effectiveness. Interferons are one of the medications that have been administered in COVID-19. Moreover, the best time of administration and dose of this medication was unknown. Although meta-analysis is a potent source for assessing the accuracy of subjects, heterogeneity of articles is a potent limitation of this work.
1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Man son JJ, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi:10.1016/S0140-6736(20)30628-0. [PubMed:32192578]. [PubMed Central:PMC7270045].
2. Arab-Zozani M, Hassanipour S. Features and limitations of LitCovid hub for quick access to literature about CO VID-19. Balkan Med J. 2020;37(4):231-2. doi:10.4274/balkan medj.galenos.2020.2020.4.67. [PubMed:32292015]. [PubMed Central:PMC7285668].
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with CO VID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi:10.1016/S0140-6736(20)30566-3. [PubMed:32171076]. [PubMed Central:PMC7270627].
4. Arab-Zozani M, Hassanipour S, Ghoddoosi-Nejad D. Fa vipiravir for treating patients with novel coronavirus (CO VID-19): Protocol for a systematic review and meta-analysis of randomised clinical trials. BMJ Open. 2020;10(7):e039730. doi:10.1136/bmjopen-2020-039730. [PubMed:32737100]. [PubMed Central:PMC7397976].
5. Khatooni E, Berenjian F, Abdi Z. Safety and efficacy of hydroxy chloroquine and chloroquine in treatment of COVID-19: A rapid review of evidence. Health Tech Asmnt Act. 2021;4(1). doi:10.18502/ htaa.v4i1.5864.
6. Mobinizadeh M, Arab-Zozani M. Safety and effectiveness of fa vipiravir for novel Coronavirus (COVID-19): A rapid review of available evidence. Health Tech Asmn Act. 2021;4(1). doi:10.18502/ htaa.v4i1.5862.
7. Hassaniazad M, Bazram A, Hassanipour S, Fathalipour M. Evalu ation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):886. doi:10.1186/s13063-020-04747-8. [PubMed:33109246]. [PubMed Central:PMC7588588].
8. Hosseini FS, Malektojari A, Ghazizadeh S, Hassaniazad M, Davoo dian P, Dadvand H, et al. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured sum mary of a study protocol for a randomized controlled trial. Trials. 2021;22(1):4. doi:10.1186/s13063-020-04988-7. [PubMed:33397429]. [PubMed Central:PMC7780209].
9. Safa O, Hassaniazad M, Farashahinejad M, Davoodian P, Dadvand H, Hassanipour S, et al. Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respira tory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):841. doi:10.1186/s13063-020-04765-6. [PubMed:33036662]. [PubMed Central:PMC7545374].
10. Safa O, Hassani-Azad M, Farashahinejad M, Davoodian P, Dadvand H, Hassanipour S, et al. Effects of Licorice on clinical symptoms and laboratory signs in moderately ill patients with pneu monia from COVID-19: A structured summary of a study pro tocol for a randomized controlled trial. Trials. 2020;21(1):790. doi:10.1186/s13063-020-04706-3. [PubMed:32933552]. [PubMed Central:PMC7490778]. 11.
11. Ziaei A, Davoodian P, Dadvand H, Safa O, Hassanipour S, Omidi M, et al. Evaluation of the efficacy and safety of mela tonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):882. doi:10.1186/s13063-020-04737-w. [PubMed:33106171]. [PubMed Central:PMC7586647].
12. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respira tory syndrome: A preliminary study. JAMA. 2003;290(24):3222-8. doi:10.1001/jama.290.24.3222. [PubMed:14693875].
13. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: Old tricks for new challenges. Crit Care. 2020;24(1):91. doi:10.1186/s13054- 020-2818-6. [PubMed:32178711]. [PubMed Central:PMC7076992]. 14. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad spectrum antivirals for the emerging Middle East respi ratory syndrome coronavirus. J Infect. 2013;67(6):606-16. doi:10.1016/j.jinf.2013.09.029. [PubMed:24096239]. [PubMed Central:PMC7112612].
15. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(Pt 3):571-7. doi:10.1099/vir.0.061911-0. [PubMed:24323636]. [PubMed Central:PMC3929173].
16. Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st respond ers. Semin Immunol. 2019;43:101300. doi:10.1016/j.smim.2019.101300. [PubMed:31771760]. [PubMed Central:PMC7128104].
17. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9(6):1003- 11. [PubMed:15651759].
18. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. doi:10.1016/j.antiviral.2020.104791. [PubMed:32275914]. [PubMed Central:PMC7138382].
19. Goodwin AJ, Li P, Halushka PV, Cook JA, Sumal AS, Fan H. Cir culating miRNA 887 is differentially expressed in ARDS and modulates endothelial function. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1261-L9. doi:10.1152/ajplung.00494.2019. [PubMed:32321279]. [PubMed Central:PMC7347270].
20. Ranieri VM, Pettila V, Karvonen MK, Jalkanen J, Nightingale P, Brealey D, et al. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: A randomized clinical trial. JAMA. 2020;323(8):725-33. doi:10.1001/ jama.2019.22525. [PubMed:32065831].
2. Arab-Zozani M, Hassanipour S. Features and limitations of LitCovid hub for quick access to literature about CO VID-19. Balkan Med J. 2020;37(4):231-2. doi:10.4274/balkan medj.galenos.2020.2020.4.67. [PubMed:32292015]. [PubMed Central:PMC7285668].
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with CO VID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi:10.1016/S0140-6736(20)30566-3. [PubMed:32171076]. [PubMed Central:PMC7270627].
4. Arab-Zozani M, Hassanipour S, Ghoddoosi-Nejad D. Fa vipiravir for treating patients with novel coronavirus (CO VID-19): Protocol for a systematic review and meta-analysis of randomised clinical trials. BMJ Open. 2020;10(7):e039730. doi:10.1136/bmjopen-2020-039730. [PubMed:32737100]. [PubMed Central:PMC7397976].
5. Khatooni E, Berenjian F, Abdi Z. Safety and efficacy of hydroxy chloroquine and chloroquine in treatment of COVID-19: A rapid review of evidence. Health Tech Asmnt Act. 2021;4(1). doi:10.18502/ htaa.v4i1.5864.
6. Mobinizadeh M, Arab-Zozani M. Safety and effectiveness of fa vipiravir for novel Coronavirus (COVID-19): A rapid review of available evidence. Health Tech Asmn Act. 2021;4(1). doi:10.18502/ htaa.v4i1.5862.
7. Hassaniazad M, Bazram A, Hassanipour S, Fathalipour M. Evalu ation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):886. doi:10.1186/s13063-020-04747-8. [PubMed:33109246]. [PubMed Central:PMC7588588].
8. Hosseini FS, Malektojari A, Ghazizadeh S, Hassaniazad M, Davoo dian P, Dadvand H, et al. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured sum mary of a study protocol for a randomized controlled trial. Trials. 2021;22(1):4. doi:10.1186/s13063-020-04988-7. [PubMed:33397429]. [PubMed Central:PMC7780209].
9. Safa O, Hassaniazad M, Farashahinejad M, Davoodian P, Dadvand H, Hassanipour S, et al. Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respira tory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):841. doi:10.1186/s13063-020-04765-6. [PubMed:33036662]. [PubMed Central:PMC7545374].
10. Safa O, Hassani-Azad M, Farashahinejad M, Davoodian P, Dadvand H, Hassanipour S, et al. Effects of Licorice on clinical symptoms and laboratory signs in moderately ill patients with pneu monia from COVID-19: A structured summary of a study pro tocol for a randomized controlled trial. Trials. 2020;21(1):790. doi:10.1186/s13063-020-04706-3. [PubMed:32933552]. [PubMed Central:PMC7490778]. 11.
11. Ziaei A, Davoodian P, Dadvand H, Safa O, Hassanipour S, Omidi M, et al. Evaluation of the efficacy and safety of mela tonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):882. doi:10.1186/s13063-020-04737-w. [PubMed:33106171]. [PubMed Central:PMC7586647].
12. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respira tory syndrome: A preliminary study. JAMA. 2003;290(24):3222-8. doi:10.1001/jama.290.24.3222. [PubMed:14693875].
13. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: Old tricks for new challenges. Crit Care. 2020;24(1):91. doi:10.1186/s13054- 020-2818-6. [PubMed:32178711]. [PubMed Central:PMC7076992]. 14. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad spectrum antivirals for the emerging Middle East respi ratory syndrome coronavirus. J Infect. 2013;67(6):606-16. doi:10.1016/j.jinf.2013.09.029. [PubMed:24096239]. [PubMed Central:PMC7112612].
15. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(Pt 3):571-7. doi:10.1099/vir.0.061911-0. [PubMed:24323636]. [PubMed Central:PMC3929173].
16. Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st respond ers. Semin Immunol. 2019;43:101300. doi:10.1016/j.smim.2019.101300. [PubMed:31771760]. [PubMed Central:PMC7128104].
17. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9(6):1003- 11. [PubMed:15651759].
18. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. doi:10.1016/j.antiviral.2020.104791. [PubMed:32275914]. [PubMed Central:PMC7138382].
19. Goodwin AJ, Li P, Halushka PV, Cook JA, Sumal AS, Fan H. Cir culating miRNA 887 is differentially expressed in ARDS and modulates endothelial function. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1261-L9. doi:10.1152/ajplung.00494.2019. [PubMed:32321279]. [PubMed Central:PMC7347270].
20. Ranieri VM, Pettila V, Karvonen MK, Jalkanen J, Nightingale P, Brealey D, et al. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: A randomized clinical trial. JAMA. 2020;323(8):725-33. doi:10.1001/ jama.2019.22525. [PubMed:32065831].
| Files | ||
| Issue | Vol 4, No 3 (2020) | |
| Section | Review Article | |
| DOI | https://doi.org/10.18502/htaa.v4i3.6347 | |
| Keywords | ||
| COVID-19 Interferons Systematic Review Meta-Analysis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Noormandi A, Fathalipour M, Daryabeygi-Khotbehsara R, Hassanipour S. The Efficacy and Safety of Interferons for the Treatment of Patients with COVID-19: Protocol for Systematic Review and Meta-Analysis of Controlled Trials. Health Tech Ass Act. 2021;4(3).
